Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France.

doi:10.1016/j.acvd.2023.07.003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France.

Archives of cardiovascular diseases - 1 Oct 2023

Damy Thibaud, Zaroui Amira, de Tournemire Marie, Kharoubi Mounira, Gounot Romain, Galat Arnault, Guendouz Soulef, Funalot Benoit, Itti Emmanuel, Roulin Louise, Audard Vincent, Fanen Pascale, Leroy Vincent, Poulot Elsa, Belhadj Karim, Mallet Sophie, Deep Singh Chadah Gagan, Planté-Bordeneuve Violaine, Gendre Thierry, Chevalier Xavier, Guignard Sandra, Bequignon Emilie, Bartier Sophie, Folliguet Thierry, Lemonier François, Audureau Etienne, Tixier Denis, Canoui-Poitrine Florence, Lefaucheur Jean-Pascal, Souvannanorath Sarah, Authier Francois-Jerome, Maupou Steven, Hittinger Luc, Molinier-Frenkel Valérie, David Jean-Philippe, Broussier Amaury, Oghina Silvia, Teiger Emmanuel

Abstract excerpt

BACKGROUND: Early cardiac amyloidosis (CA) diagnosis enables patients to access effective treatments for better long-term outcomes, yet it remains under-recognised, misdiagnosed and inadequately managed. AIM: To reduce diagnostic delays, we aimed to describe the epidemiological and clinical characteristics and changes over an 11-year period. METHODS: This was a retrospective, observational cohort study of all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Amyloid Neuropathies, Familial

Share to Cardiomyopathies

Share to Delayed Diagnosis

Share to France

Share to Predictive Value of Tests

Share to Referral and Consultation

Share to Time Factors

Source

Open in PubMed

Identifiers

PMID: 37640624
DOI: 10.1016/j.acvd.2023.07.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France.PMID 37640624Read ↗

Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Study.Semantic proximity Read ↗

Cardiac amyloidosis: when to suspect and how to confirm.Semantic proximity Read ↗

Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.Semantic proximity Read ↗

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.Semantic proximity Read ↗

Not So Rare After All: Rethinking Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Cardiac amyloidosis: the great pretender.Semantic proximity Read ↗

Systemic amyloidosis journey from diagnosis to outcomes: a twelve-year real-world experience of a single center in a middle-income countrySemantic proximity Read ↗

Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral Center.Semantic proximity Read ↗

Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis.Semantic proximity Read ↗

Multicenter study of patients with transthyretin cardiac amyloidosis in Poland: Clinical characteristics, genotyping, electrocardiographic features, outcome predictors, and tafamidis treatment outcomes.Semantic proximity Read ↗

Natural history, hospitalizations and mortality causes in ATTRv V30M amyloidosis in an endemic European cohortSemantic proximity Read ↗

A description of variant transthyretin amyloidosis (ATTRv) stage 1 patients and asymptomatic carriers in Spain: the EMPATIa study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.